Anpac BioのCDAリキッドバイオプシー技術がFast Companyの「世界を変えるアイデア賞」受賞

AsiaNet 78275 （0615）

【サクラメント（米カリフォルニア州）2019年4月11日PR Newswire＝共同通信JBN】Fast Company Magazineの編集者と審査団は、Anpac Bio-Medical Science Company（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=587923662&u=http%3A%2F%2Fwww.anpacbio.com%2F&a=Anpac+Bio-Medical+Science+Company ）の「Cancer Differentiation Analysis（がん識別分析）」（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2862663873&u=http%3A%2F%2Fwww.anpacbio.com%2Fthe-science-of-cda%2F&a=Cancer+Differentiation+Analysis ）（CDA）リキッドバイオプシー技術を国際的な2019年ヘルス＆ウェルネス「World Changing Ideas Award（世界を変えるアイデア賞）」（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3107408522&u=https%3A%2F%2Fwww.fastcompany.com%2F90329244%2Fworld-changing-ideas-2019-all-the-winners-finalists-and-honorable-mentions&a=World+Changing+Ideas+Award ）の特別賞に選定した。

Photo - https://mma.prnewswire.com/media/870121/Fast_Company_World_Changing_Ideas_Award.jpg

Photo - https://mma.prnewswire.com/media/870120/2019_Health_and_Wellness_World_Changing_Ideas_Award.jpg

Logo - https://mma.prnewswire.com/media/318127/anpac_bio_medical_science_co.jpg

「World Changing Ideas Award」（WCI）をほかに受賞したのは、IBM、インテル、アマゾン（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=618465735&u=https%3A%2F%2Fwww.amazon.com%2Fb%3Fnode%3D16008589011&a=Amazon ）、ナイキ、ボストン小児病院（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=288984106&u=http%3A%2F%2Fwww.childrenshospital.org%2F&a=Boston+Children%27s+Hospital ）、アボット、マイクロソフト、ナショナルジオグラフィック、ギリアド（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=1450226290&u=https%3A%2F%2Fwww.gileadcompass.com%2F&a=Gilead ）、Fitbit、Google、シーメンス（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3328687434&u=https%3A%2F%2Fnew.siemens.com%2Fglobal%2Fen%2Fcompany%2Ftopic-areas%2Fintelligent-infrastructure.html&a=Siemens ）、サーモフィッシャーサイエンティフィック（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2762079123&u=https%3A%2F%2Fwww.fei.com%2Fproducts%2F&a=Thermo+Fisher+Scientific ）、The Bill & Melinda Gates Medical Research Institute（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2393862475&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbill-melinda-gates-medical-research-institute%2Flife%2F%3Ftrk%3Daff_src.aff-lilpar_c.partners_pkw.10078_net.mediapartner_plc.Skimbit%2520Ltd._pcrid.449670_learning%26veh%3Daff_src.aff-lilpar_c.partners_pkw.10078_net.mediapartner_plc.Skimbit%2520Ltd._pcrid.449670_learning%26irgwc%3D1&a=The+Bill+%26+Melinda+Gates+Medical+Research+Institute ）などである。Anpac Bioは、選定に当たったFast Company審査団から「世界をよくする完成品と大胆なコンセプト」と評された。

WCI賞受賞者は世界の2000を超える候補の中から実現可能性と潜在的効果、受賞に値する「創意工夫とイノベーション促進」を基に選ばれた。

これまでに、World Nobel Prize Laureate Summit（世界ノーベル賞受賞者サミット）（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3417486409&u=http%3A%2F%2Fwww.isscnl.org%2FNewsroom%2F612.html&a=World+Nobel+Prize+Laureate+Summit ）で「流れを変える」と呼ばれて「Breakthrough Innovation Award（画期的イノベーション賞）」を受け、Global Precision Medicine Industry Awards（世界精密医療産業賞）の「Most Promising Cancer Screening Company（最も将来有望ながん検査会社）」に選ばれたAnpac Bioは最近、米国の商務省（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3711453681&u=https%3A%2F%2Fwww.mbda.gov%2Fnews%2Fblog%2F2018%2F11%2F2018-minority-health-products-and-services-firm-year&a=United+States+Department+of+Commerce ）から「Minority Health Firm of the Year（少数派のヘルス企業）」に選定された。卓越したCDAリキッドバイオプシー技術のおかげである。

Anpac Bioは、リキッドバイオプシーがん検査研究を開発した。研究対象になりうる包括的データ14万例余り（現時点）と世界的に有名な各病院（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=953145683&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fanpac-bios-liquid-biopsy-tests-catch-26-early-stage-cancers-in-single-blood-test-300594659.html&a=world-renowned+hospitals ）と主ながん研究者（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=4209632668&u=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20180204005101%2Fen%2F&a=cancer+research+leaders ）の独自の裏付けは、CDA診断が通常は疾病初期に20タイプ以上のがんを80%－90%の感度・特異度で検知し続けていることを示している。しかも、それは患者に有害な副作用を伴っておらず、生ずる「偽陽性」ははるかに少ないうえ、イメージングなど従来の検査よりコストが大幅に低く、サンプルを提出してから数分内に結果をもたらす。Anpac BioはCDA関連特許を世界で200件以上申請し、現在まで20カ国・地域で110件が発行された。

Anpac Bio最高経営責任者（CEO）のクリス・ユー博士（https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2661924556&u=http%3A%2F%2Fwww.anpacbio.com%2Fteam%2Fdr-chris-yu-co-founder-chief-executive-officer%2F&a=Chris+Yu ）は「Anpac BioチームはFast Companyの『World Changing Ideas Award』に選定されたことを大いに誇りにしたい。最も重要な世界を変えるアイデアは、疾病の早期検知と予防に関わるものだと思う。当社のCDA技術はこれらの目標を達成するために開発された。われわれは今や初期段階のがんを検知し、毎週平均2人の患者を救っている。この大きな名誉を与えてくれたFast Companyに感謝したい」と語った。

詳しい情報はAnpacBio.com を参照。

ソース：Anpac Bio-Medical Science Company

▽問い合わせ先

Drisha_Leggitt@AnpacBio.com

Anpac Bio CDA Liquid Biopsy Technology Selected by FAST COMPANY 2019 "WORLD CHANGING IDEAS AWARD"

PR78275

SACRAMENTO, California, April 11, 2019 /PRNewswire=KYODO JBN/ --

The editors and judges of Fast Company Magazine selected Anpac Bio-Medical

Science Company's (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=587923662&u=http%3A%2F%2Fwww.anpacbio.com%2F&a=Anpac+Bio-Medical+Science+Company

), "Cancer Differentiation Analysis" (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2862663873&u=http%3A%2F%2Fwww.anpacbio.com%2Fthe-science-of-cda%2F&a=Cancer+Differentiation+Analysis

) (CDA) Liquid Biopsy technology as an international, 2019 Health & Wellness

"World Changing Ideas Award" (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3107408522&u=https%3A%2F%2Fwww.fastcompany.com%2F90329244%2Fworld-changing-ideas-2019-all-the-winners-finalists-and-honorable-mentions&a=World+Changing+Ideas+Award

) Honorable Mention recipient.

Photo -

https://mma.prnewswire.com/media/870121/Fast_Company_World_Changing_Ideas_Award.jpg

Photo -

https://mma.prnewswire.com/media/870120/2019_Health_and_Wellness_World_Changing_Ideas_Award.jpg

Logo - https://mma.prnewswire.com/media/318127/anpac_bio_medical_science_co.jpg

Joining other "World Changing Ideas Award" (WCI) honorees such as: IBM, Intel,

Amazon (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=618465735&u=https%3A%2F%2Fwww.amazon.com%2Fb%3Fnode%3D16008589011&a=Amazon

), NIKE, Boston Children's Hospital (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=288984106&u=http%3A%2F%2Fwww.childrenshospital.org%2F&a=Boston+Children%27s+Hospital

), Abbott, Microsoft, National Geographic, Gilead (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=1450226290&u=https%3A%2F%2Fwww.gileadcompass.com%2F&a=Gilead

), Fitbit, Google, Siemens (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3328687434&u=https%3A%2F%2Fnew.siemens.com%2Fglobal%2Fen%2Fcompany%2Ftopic-areas%2Fintelligent-infrastructure.html&a=Siemens

), Thermo Fisher Scientific (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2762079123&u=https%3A%2F%2Fwww.fei.com%2Fproducts%2F&a=Thermo+Fisher+Scientific

), and The Bill & Melinda Gates Medical Research Institute (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2393862475&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbill-melinda-gates-medical-research-institute%2Flife%2F%3Ftrk%3Daff_src.aff-lilpar_c.partners_pkw.10078_net.mediapartner_plc.Skimbit%2520Ltd._pcrid.449670_learning%26veh%3Daff_src.aff-lilpar_c.partners_pkw.10078_net.mediapartner_plc.Skimbit%2520Ltd._pcrid.449670_learning%26irgwc%3D1&a=The+Bill+%26+Melinda+Gates+Medical+Research+Institute

), among others, Anpac Bio was recognized by Fast Company judges tasked with

identifying, "…finished products and brave concepts that make the world

better."

WCI award recipients were selected from among over 2,000 nominations worldwide,

based on feasibility and the potential for impact; and with a goal of awarding,

"ingenuity and fostering innovation."

Previously described as "game changing", and receiving the, "Breakthrough

Innovation Award", at the World Nobel Prize Laureate Summit (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3417486409&u=http%3A%2F%2Fwww.isscnl.org%2FNewsroom%2F612.html&a=World+Nobel+Prize+Laureate+Summit

); and named, "Most Promising Cancer Screening Company", at the Global

Precision Medicine Industry Awards; Anpac Bio was also recently selected by the

United States Department of Commerce (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=3711453681&u=https%3A%2F%2Fwww.mbda.gov%2Fnews%2Fblog%2F2018%2F11%2F2018-minority-health-products-and-services-firm-year&a=United+States+Department+of+Commerce

) as the, "Minority Health Firm of the Year", due to the company's remarkable,

CDA liquid biopsy technology.

Anpac Bio pioneered liquid biopsy cancer screening research. Comprehensive

research validity data from 140,000+ cases (to date), and

independently-corroborated by world-renowned hospitals (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=953145683&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fanpac-bios-liquid-biopsy-tests-catch-26-early-stage-cancers-in-single-blood-test-300594659.html&a=world-renowned+hospitals

) and cancer research leaders (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=4209632668&u=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20180204005101%2Fen%2F&a=cancer+research+leaders

), demonstrate CDA diagnostics consistently detects over 20 types of cancer,

with 80%-90% sensitivity and specificity rates -- usually at the diseases'

earliest stages. And it does so without any harmful patient side effects;

generating far fewer "false positives"; at a cost substantially lower than

traditional testing (such as imaging); and generating results within minutes of

sample submission. Anpac Bio has filed over 200 CDA-related patent applications

worldwide - 110 issued in 20 countries and regions (to date).

"Our Anpac Bio team is very proud to receive the 'World Changing Ideas'

recognition from Fast Company," states Dr. Chris Yu (

https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=2661924556&u=http%3A%2F%2Fwww.anpacbio.com%2Fteam%2Fdr-chris-yu-co-founder-chief-executive-officer%2F&a=Chris+Yu

), Anpac Bio CEO. "We believe the most important, world changing health ideas

must be related to the early detection and prevention of disease. Our CDA

technology was developed to achieve those goals. And we are now saving an

average of two patients every week by catching their cancer at the earliest

stages. We thank Fast Company for this great honor."

For further information: AnpacBio.com.

SOURCE: Anpac Bio-Medical Science Company

CONTACT:  Drisha_Leggitt@AnpacBio.com